The Economic Burden of End-Stage Renal Disease with Hyperphosphatemia: A Study of Florida Medicaid
Abstract
Background: Hyperphosphatemia is very common in patients with end-stage renal disease (ESRD). Recently, a new phosphate binder, sevelamer, has become available in the US to treat this condition. The high cost of sevelamer has significantly impacted on third-party payors such as Florida Medicaid. Calcium acetate is a less expensive drug alternative; however, unlike sevelamer, it is associated with the adverse effect of hypercalcemia. There have been few cost analyses performed on either drug. Moreover, few studies have assessed the economic impact of ESRD with hyperphosphatemia. Objectives: The aims of this study were to: (i) describe the characteristics of ESRD patients with hyperphosphatemia in terms of demographics, comorbidities, and healthcare utilization; (ii) evaluate the primary cost drivers in the treatment of these patients; and (iii) assess the cost of illness associated with treating ESRD patients with hyperphosphatemia. Methods: This retrospective study extracted data from the Florida Medicaid database. Healthcare costs were assessed from a third-party payor perspective. The patient inclusion criteria were current use of either sevelamer or calcium acetate and continuous eligibility to receive Florida Medicaid services from July 1, 1999 to December 31, 2002 with a run-in period from July 1, 1999 to December 31, 1999 to ensure that patients had been taking either of the two drugs for at least 6 months. The patient exclusion criteria were documented HIV and hemophilia. The specific direct costs included in the study were hospitalization costs, outpatient costs, emergency room costs, and prescription costs (only those for sevelamer and calcium acetate). The price year for the cost analysis was 2002. Results: A total of 10_058 recipients constituted the study sample, of which 54.0% were male and 46.0% were female. African Americans represented the largest racial group (45.6%), followed by Caucasians (28.6%). The most frequent comorbidities were hypertension, anemia, and congestive heart failure. Healthcare was most often utilized through facility visits (78.1%), followed by pharmacy-related services (17.2%) and then medical services (4.7%). Based on medical claims, the ambulance service contributed the most to healthcare utilization (8.7%), followed by recipient home visits (3.3%) and inpatient visits (2.1%). Facility claims utilization was dominated by dialysis center visits (48.5%), followed by general hospital visits (43.3%) and nursing home visits (7.4%). The major cost driver for 2000-2 was dialysis center visits ($US95 million), followed by general hospital visits ($US92 million), and prescription medication ($US11 million). The cost analysis revealed that ESRD patients with hyperphosphatemia within Florida Medicaid imposed an economic burden (including facility, medical, and prescription claims) of $US228 million for the years 2000-2. Conclusions: This is the first study to report the economic impact of ESRD with hyperphosphatemia. Given the high economic burden of this population, efforts should be undertaken to enhance preventative measures for hyperphosphatemia as well as the treatment and recovery of these patients.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic Info
Article provided by Wolters Kluwer Health | Adis in its journal Disease Management & Health Outcomes.
Volume (Year): 14 (2006)
Issue (Month): 2 ()
Pages: 99-106
Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF
Handle: RePEc:wkh:dmhout:v:14:y:2006:i:2:p:99-106
Contact details of provider:
Web page: http://diseasemanagement.adisonline.com/
For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).
Related research
Keywords: Calcium-acetate; Cost-analysis; Hospitalisation; Hyperphosphataemia; Renal-failure; Resource-use; Sevelamer;Find related papers by JEL classification:
- C - Mathematical and Quantitative Methods
- D - Microeconomics
- I - Health, Education, and Welfare
- Z - Other Special Topics
- I1 - Health, Education, and Welfare - - Health
- I19 - Health, Education, and Welfare - - Health - - - Other
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
References
No references listed on IDEASYou can help add them by filling out this form.
Citations
Lists
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:14:y:2006:i:2:p:99-106For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.